why choose us

First received: October 12, 2022

Clinical Trial: Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Merkel Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Single Arm Study With Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Immunotherapy for Patients With Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)

Brief Summary: The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma.Pembrolizumab works by helping patient's immune system to fight cancer.Lutathera works by killing cancer cells.Pembrolizumab is approved by the FDA to treat Merkel cell cancer and has caused some Merkel cell cancers to shrink and/or resolve.Lutathera is FDA-approved to treat some…

Read more